Feasibility and Acceptability of Personalized Breast Cancer Screening (DECIDO Study): A Single-Arm Proof-of-Concept Trial
Authors:
- Celmira Laza-VásquezCLCelmira Laza-Vásquez
- Montserrat Martínez-AlonsoMMMontserrat Martínez-Alonso
- Carles Forné-IzquierdoCFCarles Forné-Izquierdo
- Jordi Vilaplana-MayoralJVJordi Vilaplana-Mayoral
- Inés Cruz-EsteveICInés Cruz-Esteve
- Isabel Sánchez-LópezISIsabel Sánchez-López
- Mercè Reñé-ReñéMRMercè Reñé-Reñé
- Cristina Cazorla-SánchezCCCristina Cazorla-Sánchez
- Marta Hernández-AndreuMHMarta Hernández-Andreu
- Gisela Galindo-OrtegoGGGisela Galindo-Ortego
- Montserrat Llorens-GabandéMLMontserrat Llorens-Gabandé
- Anna Pons-RodríguezAPAnna Pons-Rodríguez
Open Access
- 21 August 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (16) , 10426
Abstract
The aim of this study was to assess the acceptability and feasibility of offering risk-based breast cancer screening and its integration into regular clinical practice. A single-arm proof-of-concept trial was conducted with a sample of 387 women aged 40–50 years residing in the city of Lleida (Spain). The study intervention consisted of breast cancer risk estimation, risk communication and screening recommendations, and a follow-up. A polygenic risk score with 83 single nucleotide polymorphisms was used to update the Breast Cancer Surveillance Consortium risk model and estimate the 5-year absolute risk of breast cancer. The women expressed a positive attitude towards varying the frequency of breast screening according to individual risk and, especially, more frequently inviting women at higher-than-average risk. A lower intensity screening for women at lower risk was not as welcome, although half of the participants would accept it. Knowledge of the benefits and harms of breast screening was low, especially with regard to false positives and overdiagnosis. The women expressed a high understanding of individual risk and screening recommendations. The participants’ intention to participate in risk-based screening and satisfaction at 1-year were very high.Keywords
Funding Information
- Instituto de Salud Carlos III (PI17/00834)
- Fondo Europeo de Desarrollo Regional (FEDER) (PI17/00834)
- Lleida Biomedical Research Institute (IRBLLEIDA) (PI17/00834)
- Universitat de Lleida (PI17/00834)
- Oncolliga Lleida (PI17/00834)
- ADIMA Lleida (PI17/00834)
This publication has 57 references indexed in Scilit:
- Breast cancer risk feedback to women in the UK NHS breast screening populationBritish Journal of Cancer, 2016
- Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast CancerJournal of Clinical Oncology, 2015
- Prediction of Breast Cancer Risk Based on Profiling With Common Genetic VariantsJNCI: Journal of the National Cancer Institute, 2015
- Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trialThe Lancet, 2015
- The Contributions of Breast Density and Common Genetic Variation to Breast Cancer RiskJNCI: Journal of the National Cancer Institute, 2015
- Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and TestsJAMA Internal Medicine, 2015
- Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast CancerPLOS ONE, 2014
- Incorporating genomics into breast and prostate cancer screening: assessing the implicationsGenetics in Medicine, 2013
- The BOADICEA model of genetic susceptibility to breast and ovarian cancerBritish Journal of Cancer, 2004
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989